Kalin Katherine Bach's Form 4 filing
SELLAS Life Sciences Group, Inc. (SLS) · filed Nov 21, 2025
- Accession no.
- 0001104659-25-114806
- Filed
- Nov 21, 2025
- Trade date
- Nov 19, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $100.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kalin Katherine BachCIK 0001832671 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 19, 2025 | Common Stock | PPurchaseAcquired | +63,400 | $1.59F1 | +$100,806 | 104,400 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reflects the weighted average purchase price of the shares of common stock purchased. These shares of common stock were purchased in multiple transactions at prices ranging from $1.555 to $1.625 per share. Ms. Kalin undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of common stock purchased at each price.
Referenced by the price of 1 transaction in Table I.